In contrast, EPO levels decrease with aging and are further reduced in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) (Brettschneider et al., 2007; Li et al., 2016; Torpel et al., 2019). This evidence concerns the gene EPO and neurodegenerative disease.